Poetra.RH / Shutterstock.com

24 September 2025NewsAmericasMarisa Woutersen

AbbVie faces secrets lawsuit over $2.1bn Capstan deal

A biotech firm specialising in mRNA therapies alleges AbbVie’s $2.1 billion Capstan purchase was built on stolen lipid nanoparticle trade secrets.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

More features

All eyes on Squires: What IP experts want from the new USPTO director

Crafting claim strategies in animal and human therapeutics

MSD scores second win in patent fight over Keytruda

Scientist jumps from Jones Day to expand rival’s biotech offering

AIPPI: Personalised medicine tests the limits in patent law

Ropes & Gray loses 21-attorney group to join rival on growth spree

How 'Boehringer' sets preliminary relief threshold for generics

‘Whose trademark law is AI based on exactly?’: Key questions from Marques